Skip to main content
Top

Episode 22 Celebrating 25 years of TKIs in CML

Marking a major milestone in chronic myeloid leukemia treatment

print
PRINT
insite
SEARCH
Guest:
Dr. Jorge Cortes

Director, Georgia Cancer Center, Augusta University, Georgia, USA

Host:
Dr. Shreeya Nanda

Senior Clinical Content Manager, Springer Medicine

Tyrosine kinase inhibitors have transformed the treatment of chronic myeloid leukemia, a condition that had limited therapeutic options before.

In this 25th year since the first phase 2 trials of the first TKI, we speak to a researcher and clinician who has been involved since the early days. Dr. Jorge Cortes shares his experience and talks about the impact of these drugs, not only in the treatment of CML but also more widely.

Read the transcript

« Previous episode: Episode 21: Moving towards migraine freedom?

Next episode: Episode 23: Improving dysphagia outcomes »

print
PRINT

Keynote webinar | Spotlight on progress in colorectal cancer

  • Live
  • Webinar | 11-12-2025 | 18:00 (CET)

CRC remains a major global health burden, but advances in screening, treatment, and lifestyle-based prevention continue to reshape clinical practice. Gain insights into how the latest research can be leveraged to optimize patient care across the CRC continuum.

Watch it live: Thursday 11 December 2025, 18:00-19:30 (CET)

Prof. Antoni Castells
Prof. Edward Giovannucci
Prof. Harpreet Wasan
Join the webinar
Webinar

Are you up to date on targeted therapies for relapsed/refractory AML? 

Join Prof. Amer Zeidan and his expert guests to hear about innovations in molecular testing, emerging therapies, and IDH-targeted treatments, and get practical advice for improving your patient care.

Supported by: independent educational grant from Rigel

Find out more
Image Credits
Medicine Matters podcast logo/© Springer Medizin Verlag GmbH, Colon cancer illustration/© (M) KATERYNA KON / SCIENCE PHOTO LIBRARY / Getty Images